natgillin/translations-raw huggingface dataset:
Medicinal products which have potential photosensitising effects (such as tetracyclines, sulphonamides, quinolones, phenothiazines, sulfonylurea hypoglycaemic agents, thiazide diuretics, griseofulvin or amiodarone) should be stopped at least 10 days before the procedure with TOOKAD and for at least 3 days after the procedure or replaced by other treatments without photosensitizing properties. 
Zdravila, ki povzročajo preobčutljivost na svetlobo Z uporabo zdravil, ki lahko povzročajo preobčutljivost na svetlobo (kot so tetraciklini, sulfonamidi, kinoloni, fenotiazini, sulfonilsečninske hipoglikemične učinkovine, tiazidni diuretiki, griseofulvin ali amiodaron), je treba prenehati vsaj 10 dni pred postopkom z zdravilom TOOKAD in jih ne uporabljati vsaj 3 dni po postopku ali pa jih zamenjati z drugimi zdravljenji, ki ne povzročajo preobčutljivosti na svetlobo.
This required urethral dilatation (see section 4.4). 
Posledično je bila potrebna dilatacija sečnice (glejte poglavje 4.4).
The chemical and physical stability of TOOKAD after reconstitution with 5 % glucose solution, in its vial, has been demonstrated for 8 hours at 15°C-25°C and at 5°C ± 3°C. 
Kemijsko in fizikalno stabilnost zdravila TOOKAD po rekonstituciji s 5-odstotno raztopino glukoze v viali, v kateri je zdravilo, so dokazali za 8 ur pri 15-25 °C in pri 5 °C ± 3 °C.
During the procedure, the optical fibres are selected and positioned transperineally into the prostate gland under ultrasound guidance to achieve a Light Density Index (LDI) ≥ 1 in the targeted tissue. 
Med postopkom so optična vlakna izbrana in z ultrazvočnim vodenjem transperinealno nameščena v prostato, da je v ciljanem tkivu dosežen indeks gostote svetlobe (LDI) ≥ 1.
This includes sunbeds, bright computer monitor screens and medical examination lights, such as ophthalmoscopes, otoscopes and endoscopy equipment, for 48 hours following the VTP procedure. 
To v 48 urah po postopku VTP vključuje solarije, bleščeče računalniške zaslone in luči za medicinske preiskave, kot so oftalmoskopi, otoskopi in oprema za endoskopijo.
If you have a history of a narrowing of the urethra or urinary flow problems, treatment may increase the risk of poor flow and urinary retention. 
Težave, povezane s sečnico Če imate anamnezo zoženja sečnice ali težave s pretokom urina, lahko zdravljenje poveča tveganje slabega pretoka in zastajanja urina.
One case of external urethral fistula occurred due to fibre misplacement (see section 4.4). 
Do enega primera zunanje fistule sečnice je prišlo zaradi nepravilne namestitve vlaken (glejte poglavje 4.4).
Short-term urinary incontinence has been observed and may result from urinary tract infection or from urgency caused by irritation to the urethra from the procedure. 
Opazili so kratkotrajno urinsko inkontinenco, ki jo lahko povzroča okužba sečil ali siljenje na vodo zaradi draženja sečnice, ki ga povzroča postopek.
After reconstitution with a 5 % glucose solution in its vial, the chemical and physical stability of TOOKAD has been demonstrated for 8 hours at 15°C-25°C and at 5°C ± 3°C. 
Po rekonstituciji zdravila TOOKAD s 5-odstotno raztopino glukoze v viali, v kateri je zdravilo, je bila kemijska in fizikalna stabilnost dokazana za 8 ur pri temperaturi 15-25 °C in za 5 °C ± 3 °C.
Post-authorisation efficacy study (PAES): In order to further investigate long-term efficacy of TOOKAD and its impact on disease progression including potential impact on the efficacy of subsequent radical therapy in patients with low risk prostate cancer as well as further characterise the long term safety of TOOKAD, the MAH should submit the results of a randomised phase 3 study in patients with localised prostate cancer compared to active surveillance (7-year follow-up study including in an depth biopsy study) (PCM301 FU5). 
Študija učinkovitosti zdravila po pridobitvi dovoljenja za promet z zdravilom (PAES): Za dodatno proučitev dolgoročne učinkovitosti zdravila TOOKAD in njegovega vpliva na napredovanje bolezni, vključno z morebitnim vplivom na učinkovitost naknadnega radikalnega zdravljenja pri bolnikih z nizko tveganim rakom prostate, in dodatno opredelitev dolgoročne varnosti zdravila TOOKAD mora imetnik dovoljenja za promet z zdravilom predložiti randomizirano študijo III. faze bolnikov z lokaliziranim rakom prostate v primerjavi z aktivnim opazovanjem (sedemletno kontrolno študijo, vključno s poglobljeno biopsijsko študijo) (PCM301
Blood lactate dehydrogenase increased Blood triglyceride increased Gamma-glutamyltransferase increased Blood cholesterol increased Blood creatine phosphokinase increased Blood potassium decreased Low density lipoprotein increased Neutrophil count increased PSA increased 
občasni zvišana raven laktat-dehidrogenaze v krvi zvišana raven trigliceridov v krvi zvišana raven gama-glutamiltransferaze zvišana raven holesterola v krvi zvišana raven kreatin-fosfokinaze v krvi znižana raven kalija v krvi zvišana raven lipoproteina nizke gostote zvečano število nevtrofilcev zvišana raven PSA zmanjšana telesna masa zvečano število belih krvnih celic
This medicinal product contains potassium and in general the dose (3.66 mg/kg) will be less than 1 mmol (39 mg) i.e. essentially ‘potassium free'. 
Uporaba pri bolnikih, ki so na dieti z nadzorovanim vnosom kalija To zdravilo vsebuje kalij in v splošnem bo odmerek (3,66 mg/kg) manjši od 1 mmol (39 mg), tj. pravzaprav „brez kalija“.
The median time to onset of urinary retention was 3 days (1-417). 
Srednja vrednost časa do nastopa zastajanja urina je znašala 3 dni (1-417).
Male sexual dysfunction (erectile dysfunction, ejaculation failure, dyspareunia, ejaculation disorder, hypospermia, painful ejaculation, retrograde ejaculation, sexual dysfunction, semen volume decreased). 
10 Motnje spolnosti pri moških (erektilna disfunkcija, neuspešna ejakulacija, dispareunija, motnje ejakulacije, hipospermija, boleča ejakulacija, retrogradna ejakulacija, motnje spolnosti, zmanjšanje količine semena).
If you have had an active inflammatory bowel disease or any condition that may increase the risk of causing abnormal connection between the rectum and the urethra (recto-urethral fistula), the treatment should be given only after careful evaluation. 
Aktivna vnetna črevesna bolezen Če je bila pri vas prisotna aktivna vnetna črevesna bolezen ali kakršno koli stanje, ki lahko poveča tveganje za nastanek nenormalne povezave med danko in sečnico (rektouretralna fistula), lahko zdravljenje prejemate le po skrbni presoji.
Planning of optical fibre positioning should be performed at the beginning of the procedure using the treatment guidance software. 
Položaj optičnih vlaken je treba s programsko opremo za usmerjanje zdravljenja nastaviti na začetku postopka.
You must remain under reduced light conditions, without exposing your skin and your eyes to daylight. 
Ostati morate v okolju s pridušeno svetlobo, kože in oči pa ne smete izpostavljati dnevni svetlobi.
AS arm N = 78 
Krak AS N = 78
The LDI corresponds to the ratio of the cumulative length of illuminated fibre tips (cm) to the volume (cc) of the targeted zone to be treated. 
Indeks LDI ustreza razmerju med kumulativno dolžino osvetljenih konic vlaken (v cm) in prostornino (v cc)
The main inclusion criteria were low-risk prostate cancer with Gleason 3 + 3 prostate adenocarcinoma as a maximum, two to three cores positive for cancer and a maximum cancer core length of 5 mm in any core (at least 3 mm for patients with only one positive core), clinical stage up to T2a, PSA ≤ 10 ng/mL, prostate volume equal or greater than 25 cc and less than 70 cc. 
Glavna merila za vključitev so bila nizko tvegani rak prostate z največ adenokarcinomom prostate z oceno po Gleasonu 3 + 3, od dva do trije stebrički, pozitivni za raka, in največja dolžina stebrička rakastega tkiva 5 mm v katerem koli stebričku (vsaj 3 mm za bolnike s samo enim pozitivnim stebričkom), klinični stadij do T2a, PSA ≤ 10 ng/ml ter prostornina prostate enaka ali večja od 25 cc in manjša od 70 cc.
In healthy human male subjects, the mean volume of distribution ranged from 0.064-0.279 L/kg, for posologies from 1.25 to 15 mg/kg of padeliporfin di-potassium indicating distribution into extracellular fluid. 
Pri zdravih moških se je srednja vrednost prostornine porazdelitve gibala od 0,064 do 0,279 l/kg pri odmerjanju od 1,25 do 15 mg/kg dikalijevega padeliporfina, kar kaže porazdelitev v zunajcelično tekočino.
The educational programme is aimed at increasing awareness and providing information concerning the signs and symptoms of certain important identified risks of padeliporfin, including photosensitivity, and also information on the existing therapeutic approaches (including VTP with 
Izobraževalni program je namenjen povečevanju ozaveščenosti in zagotavljanju informacij v zvezi z znaki in simptomi določenih pomembnih znanih tveganj padeliporfina, vključno s preobčutljivostjo na svetlobo, pa tudi informacijami o obstoječih terapevtskih pristopih (vključno s postopkom VTP z zdravilom TOOKAD) za zdravljenje določene vrste raka prostate ter morebitnih koristih, tveganjih in negotovostih postopka VTP z zdravilom TOOKAD.
Table 3 describes the co-primary efficacy endpoints in the whole prostate gland and in the treated lobe (ITT population and patients meeting the indication criteria). 
V preglednici 3 so opisani sočasni primarni opazovani dogodki učinkovitosti v celotni prostati in zdravljenem režnju (pri populaciji ITT in bolnikih, ki izpolnjujejo merila indikacije).
In vitro studies predict that TOOKAD at therapeutic concentrations is unlikely to inhibit cytochrome P450 enzymes but could inhibit OATP1B1 and OATP1B3 transporters (see section 5.2). 
Študije in vitro napovedujejo, da za zdravilo TOOKAD v terapevtskih koncentracijah ni verjetno, da bi zaviralo encime citokroma P450, lahko pa bi zaviralo prenašalce OATP1B1 in OATP1B3 (glejte poglavje 5.2).
Padeliporfin was shown to be cytotoxic in the presence of UVA irradiation (in vitro) and considered phototoxic in the guinea pig (in vivo). 
Dokazali so, da je padeliporfin citotoksičen v prisotnosti obsevanja s svetlobo UVA (in vitro), pri morskih prašičkih pa velja za fototoksičnega (in vivo).
Unspecific adverse events probably linked to the general anaesthesia were also observed: transient global amnesia, bradycardia, sinus arrhythmia, atrial fibrillation, hypotension, bronchospasm, pharyngeal inflammation, respiratory tract congestion, nausea, vomiting, constipation, pyrexia, procedural hypotension. 
Opazili so tudi nespecifične neželene učinke, ki so verjetno povezani s splošno anestezijo: prehodno globalno amnezijo, bradikardijo, sinusno aritmijo, atrijsko fibrilacijo, hipotenzijo, bronhospazem,
Abnormal clotting (fibrin D dimer increased, aPTT prolonged, INR increased). 
14 Nenormalno strjevanje krvi (povečan D-dimer fibrina, podaljšan aPTT, povečan INR).
In vitro genotoxicity testing identified padeliporfin as having weak potential to induce clastogenicity when illuminated by ultraviolet (UV); this correlates with the mechanism of action (formation of reactive oxygen species). 
S testiranjem genotoksičnosti in vitro so ugotovili, da ima padeliporfin šibko sposobnost sprožanja klastogenosti, če je osvetljen z ultravijolično (UV) svetlobo; to ustreza mehanizmu delovanja
Carcinogenicity and reproductive toxicity studies have not been conducted with padeliporfin. 
Študije kancerogenosti in vpliva na sposobnost razmnoževanja padeliporfina niso bile izvedene.
How TOOKAD is used 
Kako uporabljati zdravilo TOOKAD
Fibres to carry the laser light are inserted into the prostate gland by using hollow needles. 
Vlakna, ki prevajajo lasersko svetlobo, so z votlimi iglami vstavljena v prostato.
No patients with light-sensitive conditions such as porphyria, a history of sensitivity to sunlight or a history of photosensitive dermatitis have received TOOKAD in clinical studies. 
V kliničnih študijah noben bolnik, pri katerem je bilo prisotno stanje preobčutljivosti na svetlobo, kot je porfirija, ali pa je imel anamnezo občutljivosti na sončno svetlobo ali anamnezo fotosenzitivnega dermatitisa, ni prejemal zdravila TOOKAD.
An injection filter of 0.22 µm and an opaque tubing should be used to administer the medicinal product to the patient. 
Za dajanje zdravila bolniku je treba uporabiti injekcijski filter velikosti 0,22 µm in neprosojno cevko.
Negative biopsy in the treated lobe*, n (%) 
Negativna biopsija v zdravljenem režnju*, n
However, as the procedure includes general anaesthesia, you should not perform complex tasks like driving or using machines until 24 hours after a general anaesthetic is used. 
Ker pa postopek vključuje splošno anestezijo, 24 ur po uporabi splošnega anestetika ne smete izvajati zapletenih opravil, kot sta vožnja ali upravljanje strojev.
Pregnancy and breast-feeding TOOKAD is not indicated for the treatment of women. 
Zdravilo TOOKAD ni indicirano za zdravljenje žensk.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
TOOKAD is activated immediately after injection by shining light through the fibres from a connected laser device. 
Zdravilo TOOKAD je takoj po injiciranju aktivirano s svetlobo, ki prihaja iz priključene laserske naprave in sveti skozi vlakna.
4.7 Effects on ability to drive and use machines 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Zdravilo TOOKAD nima vpliva na sposobnost vožnje in upravljanja strojev.
In vitro studies indicate that TOOKAD is unlikely to be a substrate of OATP1B1, OATP1B3, OCT1, OATP2B1, P-gp, BCRP, MRP2 or BSEP hepatic uptake transporters. 
Študije in vitro kažejo, da za zdravilo TOOKAD ni verjetno, da bi bilo substrat prenašalcev jetrnega privzema OATP1B1, OATP1B3, OCT1, OATP2B1, P-gp, BCRP, MRP2 ali BSEP.
A similar mean clearance range was seen in patients with localised prostate cancer treated with 4 mg/kg and 2 mg/kg of padeliporfin di-potassium (0.04-0.06 L/h/kg respectively). 
Podobna srednja vrednost razpona očistka je bila opažena pri bolnikih z lokaliziranim rakom prostate, ki so bili zdravljeni s 4 mg/kg in 2 mg/kg dikalijevega padeliporfina (oziroma 0,04-0,06 l/h/kg).
Patients who have received prior VEGF therapy should take particular care to protect the eyes from light for 48 hours post TOOKAD injection. 
Bolniki, ki so bili predhodno zdravljeni proti VEGF, morajo 48 ur po vbrizganju zdravila TOOKAD še posebej skrbno varovati oči pred svetlobo.
60 watts or equivalent (i.e. 6 watts for LED lights, 12 watts for fluorescent low-energy lights). 
Uporablja lahko le žarnice z močjo največ 60 vatov ali enakovredno močjo (tj. 6 vatov pri lučeh LED, 12 vatov pri fluorescentnih nizkoenergijskih lučeh).
Post-authorisation efficacy study (PAES): In order to further investigate long-term efficacy of TOOKAD and its impact on disease progression including potential impact on the efficacy of subsequent radical therapy in patients with low risk prostate cancer (excluding very low risk) as well as further characterise the long term safety of TOOKAD, the MAH should conduct and submit the results of a long-term observational cohort study of patients with unilateral low risk localised prostate cancer treated with TOOKAD VTP (CLIN1501 PCM401). 
Do datuma raziskovanje dolgoročne učinkovitosti zdravila TOOKAD in njegovega vpliva na napredovanje bolezni, vključno z morebitnim vplivom na učinkovitost naknadnega radikalnega zdravljenja pri bolnikih z nizko tveganim rakom prostate (brez bolnikov z zelo nizkim tveganjem), in dodatno opredelitev dolgoročne varnosti zdravila TOOKAD mora imetnik dovoljenja za promet z zdravilom izvesti dolgoročno opazovalno kohortno študijo bolnikov z unilateralnim, nizko tveganim lokaliziranim rakom prostate, zdravljenim s postopkom TOOKAD VTP (CLIN1501 PCM401), in predložiti njene rezultate.
Minimal seminiferous epithelial degeneration was also recorded in one high-dose male with vacuolation. 
Pri enem od samcev z vakuolizacijo, ki je prejemal visok odmerek, je bila zabeležena tudi minimalna degeneracija semenskega epitelija.
TOOKAD-VTP should only be administered after careful clinical evaluation, to patients with a history of active rectal inflammatory bowel disease or any condition that may increase the risk of recto-urethral fistula formation (see section 4.3). 
Postopek TOOKAD-VTP se lahko pri bolnikih z anamnezo aktivne rektalne vnetne črevesne bolezni ali katere koli bolezni, ki lahko poveča tveganje za nastanek rektouretralne fistule, uporabi le po temeljiti klinični oceni (glejte poglavje 4.3).
No patients with photosensitive dermatitis, skin conditions such as porphyria or a history of sensitivity to sunlight have received TOOKAD in clinical studies. 
V kliničnih študijah noben bolnik, pri katerem je bil prisoten fotosenzitivni dermatitis ali kožne bolezni, kot je porfirija, ali pa je imel anamnezo občutljivosti na sončno svetlobo, ni prejel zdravila TOOKAD.
A similar mean distribution volume was seen in patients with localised prostate cancer treated with 2 and 4 mg/kg of padeliporfin di-potassium (0.09-0.10 L/kg respectively). 
Podobna srednja vrednost prostornine porazdelitve je bila opažena pri bolnikih z lokaliziranim rakom prostate, ki so bili zdravljeni z 2 in 4 mg/kg dikalijevega padeliporfina (oziroma 0,09-0,10 l/kg).
In vitro studies indicate that TOOKAD does not inhibit P-gp, OAT1, OAT3, OCT2, OCT1, BCRP and BSEP but it could inhibit both OATP1B1 and OATP1B3 transporters (see section 4.5). 
Študije in vitro kažejo, da zdravilo TOOKAD ne zavira P-gp, OAT1, OAT3, OCT2, OCT1, BCRP in BSEP, lahko pa bi zaviralo prenašalce OATP1B1 in OATP1B3 (glejte poglavje 4.5).
A: Rate of absence of definite cancer based on histology at 24 months Negative biopsy, n (%) 
A: Stopnja odsotnosti očitnega raka na podlagi histologije pri 24 mesecih
If you have received prior VEGF therapy, you should take particular care to protect your eyes from light for 48 hours post TOOKAD injection. 
Če ste predhodno zdravili zaradi VEGF, morate 48 ur po vbrizganju zdravila TOOKAD še posebej skrbno varovati oči pred svetlobo.
4.4 Special warnings and precautions for use 
4.4 Posebna opozorila in previdnostni ukrepi Lokalizacija tumorja
Once it has been given, TOOKAD has to be activated by laser light shone along a fibre that targets the light onto the cancer. 
Ko je zdravilo TOOKAD vneseno, ga je treba aktivirati z lasersko svetlobo, ki sije vzdolž vlakna, to pa jo usmerja v rakasto tkivo.
Urinary retention/urethral stricture 
Zastajanje urina/striktura sečnice
Urethral stenosis Urinary incontinence 
pogosti stenoza sečnice urinska inkontinenca8
It is important that all patients follow the light precautions below for 48 hours post-procedure to minimize the risk of damage to the skin and eyes. 
Za zmanjšanje tveganja poškodb kože in oči je pomembno, da vsi bolniki v 48 urah po postopku upoštevajo spodaj navedene previdnostne ukrepe v zvezi s svetlobo.
Anticoagulant medicinal products and those that decrease platelet aggregation (e.g. acetylsalicylic acid) should be stopped at least 10 days before the procedure with TOOKAD. 
Z uporabo antikoagulantnih zdravil in zdravil, ki zmanjšujejo agregacijo trombocitov (npr. acetilsalicilne kisline), je treba prenehati 10 dni pred postopkom z zdravilom TOOKAD.
One serious adverse event of prostatic abscess which was considered severe was reported in the study performed in Latin America in a patient who had a unilateral VTP procedure. 
Absces prostate V študiji, izvedeni v Južni Ameriki, so pri bolniku, pri katerem je bil izveden unilateralni postopek VTP, poročali o enem hudem neželenem učinku abscesa prostate, ki je bil ocenjen kot resen.
Digital Rectal Examination (DRE) is recommended to be performed at least once a year and more often if clinically justified.Routine biopsy is recommended at 2-4 years and 7 years post VTP, with additional biopsies based on clinical/ PSA assessment. 
Dve do štiri leta in sedem let po postopku VTP je priporočljiva rutinska biopsija, na podlagi klinične ocene/ocene PSA pa še dodatne biopsije.
The recommended dose of TOOKAD is one single dose of 3.66 mg per kg of body weight, injected into a vein. 
Priporočeni odmerek zdravila TOOKAD je en sam odmerek, vbrizgan v veno, ki znaša 3,66 mg na kg telesne mase.
• Information on the potential benefits, risks and uncertainties of VTP with TOOKAD, including: uncertainties on long-lasting benefit of TOOKAD; uncertainties on long-term safety of TOOKAD and efficacy/safety of any further treatments required such as radical prostatectomy 
TOOKAD, vključno z negotovostmi dolgoročnih koristi zdravila TOOKAD, negotovostmi dolgoročne varnosti zdravila TOOKAD in varnosti/učinkovitosti morebitnih nadaljnjih potrebnih zdravljenj, kot je radikalna prostatektomija;
It is used to treat adult men who have low-risk, localised prostate cancer in only one lobe, using a technique called Vascular-Targeted Photodynamic (VTP) therapy. 
Uporablja se za zdravljenje odraslih moških, ki imajo nizko tvegani, lokalizirani rak prostate samo v enem režnju, s postopkom,
In the Phase III European study, 20 (10.2 %) patients in the TOOKAD-VTP arm experienced genito-urinary infection. 
III. faze je 20 (10,2 %) bolnikov v kraku TOOKAD-VTP doživelo okužbo sečil.
TOOKAD-VTP arm N = 80 
Krak TOOKAD-VTP N = 80
Libido decreased Affective disorder Encopresis 
Psihiatrične motnje občasni zmanjšan libido afektivna motnja enkopreza
AS arm N = 207 
Krak AS N = 207
Prostatitis occurred in 7 (3.6 %) patients in the controlled Phase III European study. 
V kontrolirani evropski študiji III. faze se je prostatitis pojavil pri 7 (3,6 %) bolnikih.
• The approaches (including VTP with TOOKAD) for the treatment of his prostate cancer and the potential benefits, risks and uncertainties of VTP with TOOKAD: o To state that information beyond two years after the TOOKAD -VTP procedure is limited and consequently, data on the long-term efficacy and safety of TOOKADVTP are currently not available o Information on the efficacy/safety of any subsequent treatments required, such as radical prostatectomy, is currently lacking 
• pristope (vključno s postopkom VTP z zdravilom TOOKAD) k zdravljenju raka prostate pri bolniku in morebitne koristi, tveganja in negotovosti postopka VTP z zdravilom TOOKAD: o navedbo, da so informacije o obdobju po postopku TOOKAD -VTP, daljšem od dveh let, omejene ter da podatki o dolgoročni učinkovitosti in varnosti postopka TOOKAD
Other reasons d, n (%) Positive biopsy, n (%) Positive biopsy in the treated lobe*, n (%) Risk Ratio (95% CI) = 3.62 (2.50 ; 5.26) ; p value < 0.001 Risk Ratio (95% CI) = 3.24 (2.41 ; 4.36) ; p value < 0.001 Among the 60 patients who had radical therapy, 5 patients had a Month 24 biopsy For example: study withdrawal, medical reason, subject refusal Risk Ratio (95% CI) = 4.39 (2.18 ; 8.83) ; p value < 0.001 Risk Ratio (95% CI) = 4.61 (2.60 ; 8.16) ; p value < 0.001 B: Difference in rate of treatment failure associated with observed progression of disease Number of subjects progressed at Month 24, n (%) 
Drugi razlogid, n (%) Pozitivna biopsija, n (%) Pozitivna biopsija v zdravljenem režnju*, n aRazmerje tveganja (95 % CI) = 3,62 (2,50; 5,26); vrednost p < 0,001 bRazmerje tveganja (95 % CI) = 3,24 (2,41; 4,36); vrednost p < 0,001 cMed 60 bolniki, ki so bili zdravljeni radikalno, je imelo 5 bolnikov biopsijo v 24. mesecu.
Patients with abnormal clotting may develop excessive bleeding due to the insertion of the needles required to position the light fibres. 
Uporaba pri bolnikih z nenormalnim strjevanjem krvi Pri bolnikih z nenormalnim strjevanjem krvi lahko zaradi vstavljanja igel, potrebnih za namestitev svetlobnih vlaken, pride do čezmerne krvavitve.